BackPhaseRx Overview

PhaseRx Current Assets

PhaseRx's current assets is $5.8M.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$5.83M
↓ 69.43% YoYΔ $-13.24M vs prior year quarter

Peer trimmed avg / median

Loading

PhaseRx Current Assets History

Loading

PhaseRx vs. peers: Current Assets Comparison

Loading

PhaseRx Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

PhaseRx (PZRXQ) FAQ

As of the most recent data (September 2017), PZRXQ shows a current assets of $5.8M. That compares with $19M in the prior-year period — down 69.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PZRXQ's current assets is now $5.8M (was $19M) — a 69.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether PhaseRx is outperforming or lagging.

Tracking PZRXQ's current assets over time shows whether PhaseRx is scaling, shrinking, or reshaping that part of the business. The current reading is $5.8M That compares with $19M in the prior-year period — down 69.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current assets page, Stockcircle has PhaseRx's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current assets (currently $5.8M) with ownership activity and broader fundamentals.

PhaseRx's current assets is $5.8M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.